HIMS vs. NTRA, FMS, GH, OPCH, RDNT, BTSG, SHC, SGRY, PRVA, and CON
Should you be buying Hims & Hers Health stock or one of its competitors? The main competitors of Hims & Hers Health include Natera (NTRA), Fresenius Medical Care AG & Co. KGaA (FMS), Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Privia Health Group (PRVA), and Concentra Group Holdings Parent (CON). These companies are all part of the "healthcare" industry.
Hims & Hers Health vs. Its Competitors
Hims & Hers Health (NYSE:HIMS) and Natera (NASDAQ:NTRA) are both large-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, risk, profitability, media sentiment, valuation, analyst recommendations and earnings.
In the previous week, Hims & Hers Health had 71 more articles in the media than Natera. MarketBeat recorded 84 mentions for Hims & Hers Health and 13 mentions for Natera. Natera's average media sentiment score of 1.29 beat Hims & Hers Health's score of 0.17 indicating that Natera is being referred to more favorably in the news media.
Hims & Hers Health has higher earnings, but lower revenue than Natera. Natera is trading at a lower price-to-earnings ratio than Hims & Hers Health, indicating that it is currently the more affordable of the two stocks.
Hims & Hers Health has a net margin of 9.24% compared to Natera's net margin of -10.36%. Hims & Hers Health's return on equity of 22.75% beat Natera's return on equity.
63.5% of Hims & Hers Health shares are owned by institutional investors. Comparatively, 99.9% of Natera shares are owned by institutional investors. 13.7% of Hims & Hers Health shares are owned by company insiders. Comparatively, 7.6% of Natera shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Hims & Hers Health has a beta of 2.02, meaning that its share price is 102% more volatile than the S&P 500. Comparatively, Natera has a beta of 1.73, meaning that its share price is 73% more volatile than the S&P 500.
Hims & Hers Health presently has a consensus price target of $39.58, indicating a potential downside of 17.40%. Natera has a consensus price target of $184.63, indicating a potential upside of 14.32%. Given Natera's stronger consensus rating and higher possible upside, analysts plainly believe Natera is more favorable than Hims & Hers Health.
Summary
Hims & Hers Health beats Natera on 9 of the 16 factors compared between the two stocks.
Get Hims & Hers Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for HIMS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding HIMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Hims & Hers Health Competitors List
Related Companies and Tools
This page (NYSE:HIMS) was last updated on 7/3/2025 by MarketBeat.com Staff
Free HIMS Stock Alerts